Last reviewed · How we verify
Vaccine, COVID19
Vaccine, COVID19 is a Small molecule drug developed by Huashan Hospital. It is currently FDA-approved.
The COVID-19 vaccine developed by Huashan Hospital is currently marketed, positioning it as a player in the global vaccination effort against the pandemic. A key strength of the vaccine is its key composition patent, which is set to expire in 2028, providing a period of exclusivity and potential revenue protection. The primary risk to the vaccine's market position is the intense competition from other established vaccines, which may impact its adoption and sales.
At a glance
| Generic name | Vaccine, COVID19 |
|---|---|
| Sponsor | Huashan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine, COVID19 CI brief — competitive landscape report
- Vaccine, COVID19 updates RSS · CI watch RSS
- Huashan Hospital portfolio CI
Frequently asked questions about Vaccine, COVID19
What is Vaccine, COVID19?
Who makes Vaccine, COVID19?
What development phase is Vaccine, COVID19 in?
Related
- Manufacturer: Huashan Hospital — full pipeline
- Compare: Vaccine, COVID19 vs similar drugs
- Pricing: Vaccine, COVID19 cost, discount & access